MITI minimum information guidelines for highly multiplexed tissue images

Human Tumor Atlas Network

Research output: Contribution to journalComment/debate

19 Scopus citations
Original languageEnglish
Pages (from-to)262-267
Number of pages6
JournalNature Methods
Issue number3
StatePublished - Mar 2022
Externally publishedYes

Bibliographical note

Funding Information:
This work is supported by the HTAN Consortium and the Cancer Systems Biology Consortium (CSBC). A list of all current HTAN Consortium members can be found at . This work was supported by the following grants from the US National Cancer Institute under the Human Tumor Atlas Network (HTAN): U2C CA233262 (Harvard Medical School), U2C CA233280 (OHSU), U2C CA233195 (Boston DFCI Broad), U2C CA233291 (Vanderbilt University Medical Center), U2C CA233311 (Stanford University), U2C CA233238 (Boston University Medical Campus), U2C CA233285 (Children’s Hospital of Philadelphia), U2C CA233303 (Washington University St. Louis), U2C CA233280 (Oregon Health and Science University), U2C CA233284 (Memorial Sloan Kettering Cancer Center) and U2C CA233254 (Duke University Medical Center), and by other public support including U54 CA225088 (S.S., P.K.S.) and U24 CA233243 (Dana-Farber Cancer Institute, Emory University, Institute for Systems Biology, Memorial Sloan Kettering Cancer Center, Sage Bionetworks). D. Schapiro was funded by an Early Postdoc Mobility fellowship (no. P2ZHP3_181475) from the Swiss National Science Foundation and was a Damon Runyon Fellow supported by the Damon Runyon Cancer Research Foundation (DRQ-03-20); D. Schapiro is currently supported by the BMBF (01ZZ2004). N.G. was funded by the US National Institutes of Health Human BioMolecular Atlas Program (HuBMAP) OT2 OD026677 and M.D.H. by NCI/NIH Task Order No. HHSN26110071 under Contract No. HHSN2612015000031.

Funding Information:
P.K.S. is a member of the Scientific Advisory Board (SAB) or Board of Directors of Applied Biomath, RareCyte Inc. and Glencoe Software, which distributes a commercial version of the OMERO data management platform; P.K.S. is also a member of the NanoString SAB and a consultant to Merck and Montai Health. In the past five years, the Sorger laboratory has received research funding from Novartis and Merck. P.K.S. declares that none of these relationships have influenced the content of this manuscript. S.S. is a consultant for RareCyte Inc. N.G. is a co-founder and equity owner of Datavisyn. D. Schapiro is a consultant for Roche Glycart AG. J.R.S. is founder and CEO of Glencoe Software, which distributes a commercial version of the OMERO data management platform. S.J.R. receives research funding from Bristol Myers Squibb, Merck, Affimed and Kite/Gilead and is on the SAB of Immunitas Therapeutics. D. Sudar is employed by Quantitative Imaging Systems LLC. E.A.B. is an employee of Indica Labs.

Cite this